Skip to content
KStart free
AI InfrastructureDefenseQuantumAll studies →

Study of Bitopertin in Participants With EPP or XLP (APOLLO)

← catalyst calendar

NCT06910358 · readout ≤ 42 d

Sponsored by Disc Medicine, Inc (industry) · IRON — their whole pipeline →.

Phase
Phase 3
Status
Active, not recruiting
Study type
Interventional
Design
Randomized · Quadruple · Treatment
Enrollment
183actual
Sites
27
Countries
Australia, Belgium, Canada +9

Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →

Source: ClinicalTrials.gov, retrieved 2026-08-19

Dates

each axis at the precision it was filed, with the registry's own basis
DateFiledBasisWhat it is
Start2025-04-04actualWhen the study began enrolling
Primary completionSep 2026estimatedThe date the last participant is measured for the primary outcome — the readout window
Study completionOct 2026estimatedThe whole study's end, after follow-up
First posted2025-04-04actualWhen this record first appeared on the registry
Results postedWhen the sponsor posted results to the registry
Record updated2026-08-12actualThe sponsor's own last edit to this record — every projection above is as current as this date

What it studies

Conditions

  • Erythropoietic Protoporphyria (EPP)
  • X-Linked Protoporphyria (XLP)

Interventions

  • Drug: Placebo
  • Drug: DISC-1459 — also filed as Bitopertin, RO4917838

Primary outcomes

what the primary-completion date above is the date OF
Average monthly total time in sunlight on days without pain from a phototoxic reaction between 10:00 to 18:00 (10:00 AM to 6:00 PM) after 6 months (24 weeks) of treatment
measured 24 weeks
Percent change from baseline in whole-blood metal-free PPIX levels at 6 months
measured 24 weeks
Safety and tolerability, as assessed by adverse events (AEs) and laboratory results, over the 6-month treatment period
measured 24 weeks

Permalink · IRON's whole pipeline · Catalyst calendar · Every registered study · What changed